Year: 2015
Type: review
Abstract: UNLABELLED: Hepatitis C virus (HCV) drug development has resulted in treatment regimens composed of interferon-free, all-oral combinations of direct-acting antivirals. While the new regimens are potent and highly efficacious, the full clinical impact of HCV drug resistance, its implications for retreatment, and the potential role of baseline resistance testing remain critical research and clinical questions. In this report, we discuss the viral proteins targeted by HCV direct-acting antivirals and summarize clinically relevant resistance data for compounds that have been approved or are currently in phase 3 clinical trials. CONCLUSION: This report provides a comprehensive, systematic review of all resistance information available from sponsors' trials as a tool to inform the HCV drug development field.
Source: Hepatology
DOI: 10.1002/hep.27934
Authors: Erik Lontok, Patrick Harrington, Anita Howe, Tara Kieffer, Johan Lennerstrand, Oliver Lenz, Fiona McPhee, Hongmei Mo, Neil Parkin, Tami Pilot‐Matias, Veronica Miller
Institutions: University of California, Berkeley, United States Food and Drug Administration, Center for Drug Evaluation and Research, Vertex Pharmaceuticals (United States), Uppsala University, Janssen (Belgium), Bristol-Myers Squibb (United States), Gilead Sciences (United States), AbbVie (United States)
Language: English
Topic: Hepatitis C virus research
Subfield: Hepatology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $2,900
OpenAlex ID: W1826210767